Understanding the Role of Bispecific Antibodies in the Management of B-Cell Non-Hodgkin Lymphoma: A New Immunotherapy That Is Here to Stay
Lymphatics · 2023
DOI: 10.3390/lymphatics1030015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lymphatics, 2023. Verfasst von Stanislav Ivanov und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-Hodgkin lymphomas (NHLs) represent a diverse group of hematologic malignancies derived from various cells. B-cell NHLs represent the largest fraction of lymphomas diagnosed and treated in the United States. Standard chemo-immunotherapies with rituximab and multiagent cytotoxic regimens have proven to be effective in the management of these lymphoproliferative neoplasms; nonetheless, a considerable fraction of patients still experience relapse or have treatment-refractory disease. Therapeutic advances using novel immunotherapeutic agents as well as cell-based treatments, such as chimeric antigen receptor (CAR) T-cell therapies, have improved the outcomes of relapsed/refractory (R/R) B-cell NHL. Most of these new treatment strategies are not curative and most patients succumb to R/R disease, leaving this population with an unmet need for effective and well-tolerated therapeutic options. One of these up-and-coming options are bispecific antibodies (BsAb), either as single agent or in combination with other medications. Conclusion: BsAbs offer a novel “off the shelf” chemotherapy-free approach in the management of R/R B-cell NHL. Advancements in antibody construct design along with improved safety profile and clinical effectiveness of the most recent BsAbs suggest that these agents are a promising new option in the management of R/R B-cell NHL.
Zitieren
APA
Ivanov, S., Muminovic, M., & Sandoval-Sus, J. (2023). Understanding the Role of Bispecific Antibodies in the Management of B-Cell Non-Hodgkin Lymphoma: A New Immunotherapy That Is Here to Stay. Lymphatics. https://doi.org/10.3390/lymphatics1030015
Vancouver
Ivanov S, Muminovic M, Sandoval-Sus J. Understanding the Role of Bispecific Antibodies in the Management of B-Cell Non-Hodgkin Lymphoma: A New Immunotherapy That Is Here to Stay. Lymphatics. 2023. doi:10.3390/lymphatics1030015
BibTeX
@article{Ivanov2023,
author = {Ivanov, Stanislav and Muminovic, Meri and Sandoval-Sus, Jose},
title = {Understanding the Role of Bispecific Antibodies in the Management of B-Cell Non-Hodgkin Lymphoma: A New Immunotherapy That Is Here to Stay},
journal = {Lymphatics},
year = {2023},
doi = {10.3390/lymphatics1030015}
}
EUVIMED